Teva cited its “unique position as a developer of innovative medicines and high-quality generic drugs and biosimilars,” as it sued the US Centers for Medicare & Medicaid Services challenging certain aspects of drug-pricing provisions within the Inflation Reduction Act, which the Israeli firm declares “hurts not just the manufacturers of generics and biosimilars, but also weakens the US healthcare system as a whole.”
Meanwhile, in its suit Teva also attacked guidance issued by the CMS that, the firm says, “purports to implement” the IRA, “re-writing two of the critical limitations imposed by Congress...